ADAP
Adaptimmune Therapeutics
ADAP
ADAP
Delisted
ADAP was delisted on the 27th of October, 2025.
67 hedge funds and large institutions have $416M invested in Adaptimmune Therapeutics in 2017 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 21 increasing their positions, 14 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
0.63% more ownership
Funds ownership: 11.33% → 11.96% (+0.63%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Holders
67
Holding in Top 10
1
Calls
$88K
Puts
–
Top Buyers
| 1 | +$27.4M | |
| 2 | +$5.75M | |
| 3 | +$3.37M | |
| 4 |
GAMA
Graticule Asia Macro Advisors
New York
|
+$3.24M |
| 5 |
Millennium Management
New York
|
+$2.8M |
Top Sellers
| 1 | -$5.34M | |
| 2 | -$4.35M | |
| 3 | -$3.88M | |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.45M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.41M |